Review Article
Mechanisms and Therapeutic Targets of Staphylococcus Aureus - Induced Itch in Atopic Dermatitis
Issue:
Volume 7, Issue 2, December 2024
Pages:
36-40
Received:
8 July 2024
Accepted:
30 July 2024
Published:
15 August 2024
Abstract: Atopic dermatitis is a chronic skin disorder marked by inflammation, erythema, and pruritus, often beginning in childhood and characterized by exacerbations and remissions. Its etiology involves genetic, immunological, and environmental factors. Staphylococcus aureus, a common pathogen, exacerbates atopic dermatitis by producing toxins and enzymes such as the serine protease V8, which activates the protease-activated receptor 1 (PAR1) on sensory neurons, inducing itch. This mechanism highlights potential therapeutic targets for alleviating pruritus. Research into the physiological pathways of itch, including the role of PAR1 and other protease-activated receptors, reveals promising strategies for treatment. PAR1 antagonists could be repurposed to treat chronic itch, providing new therapeutic avenues. PAR1 and other protease-activated receptors, is crucial in developing new treatment strategies. Anti-pruritic therapies targeting these pathways, such as PAR1 antagonists, show promise in mitigating itch symptoms. Moreover, existing drugs that inhibit PAR1 could be repurposed for treating chronic itch, providing a new avenue for relief in patients with atopic dermatitis. Additionally, the evolutionary role of itch induced by microorganisms suggests pathogens may exploit neural reflexes to enhance their spread. Advancements in understanding the mechanisms behind S. aureus-induced itch and the physiological pathways involved offer promising new directions for therapeutic intervention. Advancements in understanding the mechanisms of Staphylococcal aureus-induced itch and associated physiological pathways offer promising directions for therapeutic intervention, potentially improving management and treatment outcomes for patients with atopic dermatitis and other pruritic conditions.
Abstract: Atopic dermatitis is a chronic skin disorder marked by inflammation, erythema, and pruritus, often beginning in childhood and characterized by exacerbations and remissions. Its etiology involves genetic, immunological, and environmental factors. Staphylococcus aureus, a common pathogen, exacerbates atopic dermatitis by producing toxins and enzymes ...
Show More
Research Article
532 nm Sub Pulsed Laser for Treating Melasma in Latin American Patients, Series of Cases
Kateryn Michelle Perez Willis*
Issue:
Volume 7, Issue 2, December 2024
Pages:
41-47
Received:
9 August 2024
Accepted:
27 September 2024
Published:
29 October 2024
Abstract: Objective: To analyze a series of cases treated with a 532 nm Sub Pulsed laser treatment for Melasma in Latin American Patients with Fitzpatrick type IV. Background: Melasma is a common, acquired, symmetrical hypermelanosis that presents as light to dark brown macules on the face usually over the forehead and malar areas that negatively impact patient’s quality of life. Many laser treatments have been described without any consensus, however, targeting the vascular component has been gaining popularity daily but the adverse reactions such as transient post inflammatory hyperpigmentation or atrophic scars have been described for treating the superficial and deep vessels. We propose a new laser range in order to treat Melasma. Methods: This is an observational study with 20 patients, Fitzpatrick type IV diagnosed with facial melasma that were treated with one to two sessions of a Sub Pulsed 532 nm Laser with an interval of 11 to 30 days. Dermoscopy was performed in the patients before the laser in order to show the presence of multiple vessels and pigmentation in the patients, before and after pictures were taken with Quantificare Lifeviz to show the results after the laser without any other topical or oral treatment. This Study was reviewed and approved by the Ethics and Investigation Committee of Dermalaser KPW in Lima, Peru, adhering to the highest ethical standards and following the principles Outlined in the Helsinsky Declaration. Informed Consent was obtained from all participants, who also provided written authorization for the publication of the study results and accompanying images. Results: In this series of cases the Modified MASI Score describes an average of 90.9% improvement in Melasma severity after the laser sessions. The pictures taken with Quantificare Lifeviz in order to asses the vascular, pigmentary and basal pictures show significant improvement. No PIH (Post inflammatory Hyperpigmentation) or major adverse reaction were described in this study.
Abstract: Objective: To analyze a series of cases treated with a 532 nm Sub Pulsed laser treatment for Melasma in Latin American Patients with Fitzpatrick type IV. Background: Melasma is a common, acquired, symmetrical hypermelanosis that presents as light to dark brown macules on the face usually over the forehead and malar areas that negatively impact pati...
Show More
,
Valentina Broshtilova
